Peapod Lane Capital LLC Makes New $833,000 Investment in Ikena Oncology, Inc. (NASDAQ:IKNA)

Peapod Lane Capital LLC acquired a new stake in Ikena Oncology, Inc. (NASDAQ:IKNA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 507,868 shares of the company’s stock, valued at approximately $833,000. Peapod Lane Capital LLC owned about 1.05% of Ikena Oncology at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Ikena Oncology by 5.6% in the 3rd quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock valued at $469,000 after acquiring an additional 14,319 shares during the period. FMR LLC grew its position in Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. AQR Capital Management LLC acquired a new position in Ikena Oncology in the second quarter valued at $36,000. NEA Management Company LLC raised its holdings in shares of Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after buying an additional 30,013 shares during the last quarter. Finally, BBR Partners LLC boosted its stake in shares of Ikena Oncology by 550.0% during the third quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock worth $225,000 after buying an additional 110,000 shares during the period. 75.00% of the stock is owned by institutional investors and hedge funds.

Ikena Oncology Stock Performance

Shares of Ikena Oncology stock opened at $1.46 on Thursday. Ikena Oncology, Inc. has a one year low of $1.22 and a one year high of $1.94. The firm has a fifty day moving average of $1.56 and a two-hundred day moving average of $1.65.

Wall Street Analyst Weigh In

IKNA has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush reiterated a “neutral” rating and issued a $2.00 target price on shares of Ikena Oncology in a research note on Monday, December 23rd.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.